The UK medicines regulator, the MHRA, is joining yet another established international regulatory collaboration for speeding up drug evaluations when the Brexit transition period ends – this time the Australia-Canada-Singapore-Switzerland (ACSS) Consortium.
The move was revealed on 14 October, just over a week after the UK government announced that the MHRA was...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?